COPD Clinical Trial
Official title:
Analysis of the Time Taken for Newly Diagnosed COPD Patients to be Prescribed Triple Therapy
The proposed study will evaluate (for newly diagnosed Chronic Obstructive Pulmonary Disease
(COPD) patients)the time taken to prescription of triple therapy by aiming to answer these
following research questions:
1. The percentage of patients prescribed triple therapy, and when they first started
receiving triple therapy.
2. For patients prescribed triple therapy, the time taken to triple therapy from initial
diagnosis of COPD.
3. The variation in treatment pathways.
4. The factors associated with time taken to triple therapy.
Triple therapy consists of long-acting beta agonist (LABA) + inhaled corticosteroids (ICS) +
long-acting muscarinic antagonist (LAMA) and typically should be reserved for patients who
have severe to very severe (FEV1 <50%) COPD symptoms or for patients who have two or more
exacerbations per year. However previous research from RiRL indicate that 50% of patients at
GOLD stage II (moderate) receive ICS of which half were on triple therapy.
To allow for multiple analysis regarding the factors that influence the likelihood of being
prescribed triple therapy, a bespoke COPD dataset will be created to include:
1. Disease severity markers:
2. Confirmation of a COPD diagnosis at initial date of COPD diagnosis
3. Standard co-morbidities fields
4. Demographic fields
This retrospective, observational study using data of COPD patients will assess treatment
pathways (changes/step up) from initial date of COPD diagnosis with the prescription of
triple therapy as the endpoint.
Specific questions that will be asked are:
1. Does the percentage of COPD patients prescribed triple therapy vary dependent on time
of initial date of COPD diagnosis?
2. Does the time taken to the prescription of triple therapy vary dependent on initial
date of COPD diagnosis?
;
Observational Model: Cohort, Time Perspective: Retrospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT06000696 -
Healthy at Home Pilot
|
||
Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
Completed |
NCT04043728 -
Addressing Psychological Risk Factors Underlying Smoking Persistence in COPD Patients: The Fresh Start Study
|
N/A | |
Completed |
NCT04105075 -
COPD in Obese Patients
|
||
Recruiting |
NCT05825261 -
Exploring Novel Biomarkers for Emphysema Detection
|
||
Active, not recruiting |
NCT04075331 -
Mepolizumab for COPD Hospital Eosinophilic Admissions Pragmatic Trial
|
Phase 2/Phase 3 | |
Terminated |
NCT03640260 -
Respiratory Regulation With Biofeedback in COPD
|
N/A | |
Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|
||
Withdrawn |
NCT04210050 -
Sleep Ventilation for Patients With Advanced Hypercapnic COPD
|
N/A | |
Terminated |
NCT03284203 -
Feasibility of At-Home Handheld Spirometry
|
N/A | |
Recruiting |
NCT06110403 -
Impact of Long-acting Bronchodilator- -Corticoid Inhaled Therapy on Ventilation, Lung Function and Breathlessness
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT06040424 -
Comparison of Ipratropium / Levosalbutamol Fixed Dose Combination and Ipratropium and Levosalbutamol Free Dose Combination in pMDI Form in Stable Chronic Obstructive Pulmonary Disease (COPD) Patients
|
Phase 3 | |
Recruiting |
NCT05865184 -
Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
|
||
Recruiting |
NCT04868357 -
Hypnosis for the Management of Anxiety and Breathlessness During a Pulmonary Rehabilitation Program
|
N/A | |
Completed |
NCT01892566 -
Using Mobile Health to Respond Early to Acute Exacerbations of COPD in HIV
|
N/A | |
Completed |
NCT04119856 -
Outgoing Lung Team - a Cross-sectorial Intervention in Patients With COPD
|
N/A | |
Completed |
NCT04485741 -
Strados System at Center of Excellence
|
||
Completed |
NCT03626519 -
Effects of Menthol on Dyspnoea in COPD Patients
|
N/A | |
Recruiting |
NCT04860375 -
Multidisciplinary Management of Severe COPD
|
N/A |